Price

US$ 73,94

variation (12m)

8,53% Logo

p/l

32,24

p/vp

4,27

DIVIDEND YIELD

0,00%
graph

price EW

BVMF
EW
If you had invested
If you had invested
years ago
6 months
1 year
5 years
10 years
ago, today you would have
ago, today you would have:
*The figure considers the reinvestment of dividends.

Profitability of EW

1 month
3 months
1 year
2 years
5 years
10 years
profitability
1 month
-5,54%
3 months
-5,27%
1 year
8,53%
2 years
5,75%
5 years
-13,03%
10 years
207,21%

real profitability

profitability minus inflation.

1 month
-5,54%
3 months
-5,62%
1 year
3,77%
2 years
-3,48%
5 years
-35,73%
10 years
83,93%
Estatistica

Indicators EW

check out the fundamentals of Edwards Lifesciences shares

P/E

32,24
Sector: -1,19 Industry: -3,13

P/SALES RATIO (PSR)

7,72
Sector: 1,95 Industry: 2,78

P/BV

4,27
Sector: 2,22 Industry: 1,88

DIVIDEND YIELD (DY)

0,00%
Sector: - Industry: -

ROA

10,40%
Sector: -26,82% Industry: -52,06%

ROE

13,23%
Sector: -29,98% Industry: -40,51%

ROIC

17,19%
Sector: -411,56% Industry: -412,66%

NET MARGIN

23,93%
Sector: -27,32% Industry: -30,04%

GROSS MARGIN

78,12%
Sector: 43,14% Industry: 44,05%

OPERATING MARGIN

27,72%
Sector: -23,36% Industry: -26,70%

P/EBITDA

24,22
Sector: 0,02 Industry: -2,09

P/EBIT

26,41
Sector: -1,26 Industry: -2,90

P/ASSET

3,35
Sector: 1,27 Industry: 1,41

BVPS

18,07
Sector: 3,73 Industry: 1,64

EPS

2,39
Sector: -0,77 Industry: -1,17

EQUITY / ASSETS

0,79
Sector: 0,45 Industry: 0,48

CAGR REVENUES 5 YEARS

5,92%
Sector: - Industry: -

CAGR PROFITS 5 YEARS

10,86%
Sector: - Industry: -
RETORNO DO INVESTIMENTO

FAIR PRICE OF Edwards Lifesciences ASSETS ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Price

The Fair Price formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffet's mentor.

Current price

US$ 73,94

Fair Price

US$ 0,00

Upside Potencial de rentabilidade.

-57,84%
Because it considers equity value in its calculation, the formula does not work well for technology companies.
This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.
statistics

EW indicators history

Buy And Hold Investor Checklist

Buy and hold investor checklist on Edwards Lifesciences

Stocks comparator

graph

comparison of EW with indexes

If you had invested (change) 2 years years ago, ago, today you would have

R$ 1.000,00 in PETR4 you would have R$ 2.294,60

R$ 1.000,00 in LEVE3 you would have R$ 5.240,60

*The value considers the reinvestment of dividends.
Cotação

Dividend History EW

current DY: 0,00%

5-year average DY: 0,00%

no dividend paid in the period.

ABOUT THE COMPANY

Logo Edwards Lifesciences

Edwards Lifesciences Corp.

Average user rating I10

4.0 (11 people)

Estados Unidos

Estados Unidos

26 years

Foundation: 1999

2000

Year of debut on the stock exchange - 25 years

14.900

Employees

Market value

US$ 45,24 Billions

US$ 45,24 Billions

Net worth

US$ 10,61 Billions

US$ 10.606.500.000,00

Assets

US$ 13,49 Billions

US$ 13.488.700.000,00

Total Number of Shares

587,00 Milhões

587.000.000

Average Daily Trading Volume

US$ 4,54 Milhões

US$ 4.542.416,00

Sector

Health

Industry

Medical Supplies and Equipment

Shares

receitas e lucros

EW revenue and profits

graph

PROFIT X PRICE EW

resultados

EW results

DRAG THE FRAME TO SEE MORE DATA
Resultados

EW cash flow

DRAG THE FRAME TO SEE MORE DATA
Ativos e Passivos

evolution of assets - EW

Pontos Relevantes

EW balance sheet

DRAG THE FRAME TO SEE MORE DATA

Frequently Asked Questions

What is the price of Edwards Lifesciences (EW) today?

The price of Edwards Lifesciences (EW) today is US$ 73,94, with a variation of 8.53% compared to the last year. The price of Edwards Lifesciences (EW) started the year trading around US$ 74,03 and today it is at US$ 73,94. Follow the real-time price chart, the historical price of Edwards Lifesciences (EW), and stock data from Ibovespa and international markets.

When does Edwards Lifesciences (EW) pay dividends?

Edwards Lifesciences (EW) did not distribute dividends in the last year.

Edwards Lifesciences (EW) is it worth it?

Currently, Edwards Lifesciences (EW) is priced at US$ 73,94, with a P/E of 32,24%, representing a deviation of 30,34% from its historical average P/E. In the last year, the stock showed a variation of 8.53% in its price and distributed US$ 0,00 in dividends, resulting in a Dividend Yield of 0,00%. The total shareholder return was 8,53%.

It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

How to buy stocks of Edwards Lifesciences (EW)?

Investing in stocks of Edwards Lifesciences (EW) can be done in two ways: by buying the stock no exterior. A stock is the original stock, traded on international exchanges. By buying it, you invest with money outside Brazil, which brings greater geographical and currency diversification.

BDR is a receipt for that stock, traded on the B3 with reais, through a brazilian brokerage. Although the money remains in Brazil, the BDR still offers diversification, as it represents a foreign company and is linked to the dollar.

How much do 100 stocks of Edwards Lifesciences (EW) yield today?

The yield of Edwards Lifesciences (EW) was -5,54% in the last month, 8,53% in the last year and -13,03% in the last 5 years (already considering appreciation and dividends).

In the last 12 months, the company paid a total of US$ 0,00 in dividends, um Dividend Yield de 0,00%.

If you wanted to buy 100 stocks of Edwards Lifesciences (EW) today, the total investment would be US$ 7.394,00, based on the current price of US$ 73,94.

If past performance were to repeat, the return on your investment would be:

  • In 1 year: US$ 8.024,71
  • In 5 years: US$ 6.430,56
  • In 10 years: 22.715,11

It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.